In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab ...

Median OS near 2 years in phase III makes case for new standard of care ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced updated clinical results that show promising anti-tumor activity and ...

In patients with extensive-stage small cell lung cancer, adding tarlatamab to durvalumab maintenance therapy significantly ...

Researchers have uncovered a hidden immune defense capable of attacking small cell lung cancer, an extremely aggressive ...

"The ADRIATIC Trial: Consolidation Immunotherapy in Limited-Stage SCLC" takes up the trial that the panel calls the biggest ...

The full look at the results of the DeLLphi-305 study of Imdelltra (tarlatamab) and Imfinzi (durvalumab) as first-line maintenance therapy for extensive-stage SCLC (ES-SCLC) whose disease had not ...

A 2026 literature review synthesizes clinical, diagnostic, molecular and therapeutic evidence on transformation from ...

Mona Bratter had trouble breathing after surgery in 2023 to treat her small-cell lung cancer (SCLC). But when her oncologist suggested palliative care to help manage her discomfort, she was hesitant. ...

Stereotactic radiosurgery (SRS) may offer an alternative to hippocampal-avoidant whole-brain radiotherapy (WBRT) for brain metastases from small cell lung cancer (SCLC), according to the first ...

Transcription factors, especially FOXP1, are crucial in SCLC chemoresistance, influencing drug sensitivity and resistance pathways. FOXP1 regulates SP8 expression via its super-enhancer, impacting the ...